The PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.
The PARTNERS trial opened BVD enrollment July 2, 2026, testing MBP134 and obeldesivir for a hemorrhagic fever that kills...
What a Single-Dose Synthetic Psychedelic Teaches Us About the Limits of Our TRD Trial Designs
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...
What Semaglutide’s Fentanyl Data Should Mean for How We Design the Next OUD Trial
New preclinical data shows semaglutide cuts fentanyl self-administration in rats, and raises hard questions about OUD trial design for...
Imviva Gets FDA Clearance for clonoSEQ in CTD402 T-ALL Trial
Imviva gains FDA clearance for clonoSEQ in CTD402 T-ALL trial, enabling MRD-driven patient management decisions in allogeneic CAR-T therapy...
Brii Bio’s ENRICH Study Shows 42.9% HBsAg Loss in Hepatitis B
Brii Bio's ENRICH study demonstrates 42.9% HBsAg loss in hepatitis B patients, but Phase 3 advancement faces legal constraints...
Revolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancer
Revolution Medicines reports 82% response rate for zoldonrasib in metastatic pancreatic cancer, with Phase 3 trials underway in first-line...
Your AI Scored 92% on the Medical Exam. That Number Is Lying to You.
Health AI acing benchmarks while failing real clinical tasks exposes a validation gap that trial sponsors and the FDA...
When Your Drug Supplier Gets a Warning Letter: What Genzyme Ireland Means for Trial Supply Planning
FDA issued a Warning Letter to Genzyme Ireland on June 22, 2026, over CGMP violations at its Waterford site....
Abbisko, AstraZeneca Begin Phase I/II Trial of Lumipodlin With Osimertinib in EGFR-Mutant NSCLC
Abbisko and AstraZeneca begin Phase I/II trial combining lumipodlin with osimertinib in EGFR-mutant NSCLC patients with high PD-L1 expression.
The Pediatric CNS Immunotherapy Signal That Sponsors Are Underreading
ReMIND's multi-antigen T cell data in 25 pediatric CNS patients points to a regulatory inflection point sponsors haven't mapped...